ArticleThe Biochemical journal1987
Neutrophil association and degradation of normal and acute-phase high-density lipoprotein 3.
Article in The Biochemical journal, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 38 citations in OpenAlex.
- SAA: a link between cholesterol efflux capacity and inflammation?Journal of lipid research · 2015Article
- The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection.Virology journal · 2010Article
- Identification in milk of a serum amyloid A peptide chemoattractant for B lymphoblasts.BMC immunology · 2009Article
- Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection.PLoS pathogens · 2009Article
- High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study.Atherosclerosis · 2007Article
- Article
- Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis.The Biochemical journal · 1999Article
- Regulation of serum amyloid A protein expression during the acute-phase response.The Biochemical journal · 1998Review
- Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2.The Biochemical journal · 1995Article
- Phosphorylation of human serum amyloid A protein by protein kinase C.The Biochemical journal · 1988Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction of normal and acute-phase high-density lipoproteins of the subclass 3 (N-HDL3 and AP-HDL3) with human neutrophils and the accompanying degradation of HDL3 apolipoproteins have been studied in vitro. The chemical composition of normal and acute-phase HDL3 was similar except that serum amyloid A protein (apo-SAA) was a major apolipoprotein in AP-HDL3 (approx. 30% of total apolipoproteins). 125I-labelled AP-HDL3 was degraded 5-10 times faster than 125I-labelled N-HDL3 during incubation with neutrophils or neutrophil-conditioned medium. Apo-SAA, like apolipoprotein A-II (apo-A-II), was more susceptible than apolipoprotein A-I (apo-A-I) to the action of proteases released from the cells. The amounts of cell-associated AP-HDL3 apolipoproteins at saturation were up to 2.8 times greater than N-HDL3 apolipoproteins; while apo-A-I was the major cell-associated apolipoprotein when N-HDL3 was bound, apo-SAA constituted 80% of the apolipoproteins bound in the case of AP-HDL3. The associated intact apo-SAA was mostly surface-bound as it was accessible to the action of exogenous trypsin. alpha 1-Antitrypsin-resistant (alpha 1-AT-resistant) cellular degradation of AP-HDL3 apolipoproteins also occurred; experiments in which pulse-chase labelling was performed or lysosomotropic agents were used indicated that insignificant intracellular degradation occurred which points to the involvement of cell-surface proteases in this degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.